While eseramine has a less inhibitory effect against acetylcholinesterase than physostigmine, physovenine was patented as an inhibitor of acetylcholinesterase and butyrylcholinesterase as well as for the treatment of AD and dementia. The gene discussed is BCHE; the disease is dementia.